Calidi Biotherapeutics Reports Second Quarter Progress
Calidi Biotherapeutics Inc. (NYSE: CLDI), a clinical-stage biotechnology company, is making strides in the realm of targeted therapies. The recent financial results and operational developments highlight their forward momentum in advancing innovative treatments.
Key Operational Highlights
During the latest quarter, the company showcased preclinical advancements at a prestigious oncology conference. They presented vital data on CLD-401, emphasizing its biological effectiveness by delivering the IL-15 superagonist to metastatic tumor sites. This engineered compound aims to decrease immune clearance, thus fortifying the potential for systemic treatments in oncology.
Achievements in FDA Designations
A noteworthy achievement during this quarter was obtaining Fast Track Designation from the FDA for CLD-201. This first-in-class therapy uses a stem-cell loaded oncolytic virus targeting soft tissue sarcoma, bringing hope to patients with limited options.
Financial Overview for the Second Quarter
Calidi reported a net loss attributable to common stockholders of $5.7 million for the three months ended June 30, 2025. This translates to $1.99 per share, showcasing a significant improvement from $7.4 million reported for the same period in 2024. Such a reduction in losses could indicate efficient management and a more robust operational strategy.
Changes in Research and Development Expenses
Research and development expenditures were noted at $2.6 million, reflecting a slight increase from the previous year's expenses of $2.2 million. Simultaneously, general and administrative costs decreased to $3.1 million compared to $3.6 million in the year-ago quarter.
Liquidity Position
As of June 30, 2025, Calidi had approximately $5.3 million in cash reserves, down from $9.6 million as of December 31, 2024, which emphasizes the importance of navigating their financial footing responsibly.
Looking Ahead: Future Initiatives
The company is progressing towards the filing of an Investigational New Drug (IND) application for their promising therapies, further showcasing their commitment to innovation in the biotechnology landscape.
About Calidi Biotherapeutics
Calidi Biotherapeutics, utilizing its advanced RedTail platform, is at the forefront of immuno-oncology advancements. By employing engineered enveloped viruses, they aim to deliver genetic treatments effectively to metastatic disease areas. Their approach is supported by substantial preclinical data, confirming the urgency and need for innovative therapeutic developments in this field.
Investor and Media Contacts
For additional information regarding Calidi Biotherapeutics, interested parties can connect with Dave Gentry, CEO of RedChip Companies, Inc., at 1-407-644-4256 or email CLDI@redchip.com.
Frequently Asked Questions
What progress has Calidi Biotherapeutics made recently?
Calidi Biotherapeutics has showcased significant preclinical data on CLD-401, demonstrating effective therapies aimed at metastatic tumors.
What recent FDA designations did Calidi achieve?
Calidi received Fast Track Designation for CLD-201, a new therapy targeting soft tissue sarcoma.
How did Calidi's financials perform in Q2 2025?
Calidi reported a $5.7 million loss in Q2 2025, an improvement compared to $7.4 million the prior year.
What are the company's cash reserves as of June 2025?
The company's cash reserves stood at approximately $5.3 million as of June 30, 2025.
How does Calidi plan to advance its therapies?
Calidi aims to file an IND for its therapies while continuing to explore innovative treatment options for patients in need.
